Literature DB >> 6208913

Sjögren's syndrome. Influence of multiple HLA-D region alloantigens on clinical and serologic expression.

R W Wilson, T T Provost, W B Bias, E L Alexander, D W Edlow, M C Hochberg, M B Stevens, F C Arnett.   

Abstract

The relationships of HLA-DR and the newer DS (second D locus) B cell alloantigens (MB and MT) to the clinical and serologic expression of primary and secondary forms of Sjögren's syndrome (SS) were examined in 102 patients (86 whites and 16 blacks). Although HLA-DR3 was significantly increased in whites (25 of 50, 50%) and blacks (4 of 5, 80%) with primary SS compared with race-matched normal controls, it was not appreciably elevated in those with systemic lupus erythematosus (SLE)-SS, rheumatoid arthritis (RA)-SS, or connective tissue disease-SS. The MT2 specificity, however, was more strongly associated with primary SS (86% of whites and 100% of blacks) and also with SLE-SS and RA-SS compared with race-matched normal controls. Furthermore, MT2 was significantly increased in SLE-SS and RA-SS when compared with non-sicca SLE and RA controls. Although primary and secondary SS were most strongly associated with this DS specificity (MT2), the anti-Ro (SS-A) and anti-La (SS-B) antibody responses were more closely allied to DR antigens. HLA-DR3 was increased in anti-Ro positive patients, both whites and blacks, with primary SS (74%) and in total anti-Ro positive subjects (54%) compared with their anti-Ro negative counterparts (38% and 31%, respectively). Among DR3 negative patients, HLA-DR2 correlated with anti-Ro in both primary SS (83%) and in the total SS group (58%). Thus, 96% of Ro antibody positive patients with primary SS had DR3 and/or DR2, as did 80% of anti-Ro positive subjects in all categories.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208913     DOI: 10.1002/art.1780271106

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

Review 1.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

Review 2.  B-cell epitopes of La and Ro autoantigens.

Authors:  S Whittingham
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 3.  Anti-Ro (SSA)/La (SSB) antibodies and Sjögren's syndrome.

Authors:  H M Moutsopoulos; L V Zerva
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 4.  Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.

Authors:  Ibtisam Al-Hashimi
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Significance of the Ro antigen system.

Authors:  M Reichlin
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

6.  The genetic basis of Ro and La antibody formation in systemic lupus erythematosus. Results of a multicenter study. The SLE Study Group.

Authors:  K Hartung; H Ehrfeld; H J Lakomek; R Coldewey; B Lang; F Krapf; R Müller; D Schendel; H Deicher; H P Seelig
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

7.  Immunogenetic markers in rheumatic diseases.

Authors:  L Martin; M J Fritzler
Journal:  Can Fam Physician       Date:  1990-03       Impact factor: 3.275

Review 8.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

9.  Polymorphisms of the mannose binding lectin gene in patients with Sjögren's syndrome.

Authors:  Z Y Wang; A Morinobu; S Kanagawa; S Kumagai
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

10.  High-resolution HLA analysis of primary and secondary Sjögren's syndrome: a common immunogenetic background in Mexican patients.

Authors:  Gabriela Hernández-Molina; Gilberto Vargas-Alarcón; Jose M Rodríguez-Pérez; Nancy Martínez-Rodríguez; Guadalupe Lima; Jorge Sánchez-Guerrero
Journal:  Rheumatol Int       Date:  2014-09-28       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.